Test tubes are seen in front of a displayed Moderna logo in this illustration taken, May 21, 2021. [Photo/Agencies] LOS ANGELES - The US government on Tuesday announced a 176-million-US-dollar ...

Farley did not elaborate on his views, but he is hardly the only Fortune 500 CEO who believes AI could spell trouble for ...

Moderna logo is seen in Warsaw, Poland on April 9, 2025. (Photo by Jakub Porzycki/NurPhoto via Getty ... More NurPhoto via Getty Images Moderna’s stock (NASDAQ: MRNA) has fallen over 80% in the ...

Moderna announced Wednesday that the Trump administration has canceled a major contract worth nearly $700 million for the development of its bird flu vaccine. This decision ends a key pandemic ...

Moderna has pulled the filing for FDA approval of its flu/COVID combination vaccine. The biotech plans to resubmit later this year with the phase 3 flu vaccine efficacy data the agency wants to see.

Moderna's plans include a $1.1 billion reduction in R&D expenses by 2027 to a range of $3.6 billion to $3.8 billion. Rather than spending to explore new products, the company will shift its focus ...

Test tubes are seen in front of a displayed Moderna logo in this illustration taken, May 21, 2021. [Photo/Agencies] LOS ANGELES - The US government on Tuesday announced a 176-million-US-dollar ...

Moderna said on Wednesday it has entered into an agreement with private equity firm Blackstone's life science investment platform for a funding of $750 million to develop its mRNA flu vaccines.

SHANGHAI - American biotech company Moderna on Monday commenced construction on its first pharmaceutical plant in China, with an estimated investment of 3.6 billion yuan ($501 million).

Moderna on Wednesday said clinical trial data showed its updated COVID-19 vaccine will likely be effective against the highly-mutated BA.2.86 subvariant of the coronavirus that has raised fears of ...

For now, however, Moderna remains a one-trick COVID-19 vaccine pony. Helpfully, it gave investors a shot of good news on that front following its earnings report.

Moderna currently has five vaccine candidates in clinical development to combat influenza, which kills between 290,000 and 650,000 people worldwide every year, the company said.